Abstracts tagged "ocular involvement and treatment"

Abstract Number: 622 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Dry Eyes
Frederick B Vivino¹, Gary Foulks², S. Lance Forstot³, Peter Donshik⁴, Joseph Forstot⁵, Michael Goldstein⁶, Michael Lemp⁷, J. Daniel Nelson^8,9, Kelly K. Nichols^10,11, Stephen C. Pflugfelder¹², Jason Tanzer¹³, Penny Asbell¹⁴, Deborah S. Jacobs^15,16, Katherine M Hammitt¹⁷ and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY, ³Corneal Consultants of Colorado, Littleton, CO, ⁴Department of Ophthalmology, University of Connecticut Health Center, Farmington, CT, ⁵Rheumatology Associates of South Florida, Boca Raton, FL, ⁶New England Eye Center, Tufts Medical Center, Boston, MA, ⁷Department of Ophthalmology, Georgetown University, Washington, DC, ⁸Ophthalmology, HealthPartners Specialty Center, St. Paul, MN, ⁹Dept. of Ophthalmology, University of Minnesota, St. Paul, MN, ¹⁰School of Optometry, The University of Alabama at Birmingham, Birmingham, AL, ¹¹College of Optometry, (formerly) University of Houston, Houston, TX, ¹²Ocular Surface Center, Baylor College of Medicine, Cullen Eye Institute, Houston, TX, ¹³Department of Oral Health and Diagnostic Sciences, University of Connecticut School of Dental Medicine, Farmington, CT, ¹⁴Dept of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁵Boston Foundation for Sight, Needham, MA, ¹⁶Cornea and External Diseases, Massachusetts Eye and Ear, Boston, MA, ¹⁷Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD
Background/Purpose: Dry eyes can compromise quality of life in Sjogren’s Syndrome (SS) and is often one of the most troublesome symptoms. Clinical practice guidelines were…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].